LENZ Stock Summary and Trading Ideas (Lenz Therapeutics | NASDAQ:LENZ)

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

Lenz Therapeutics trades on the NASDAQ stock market under the symbol LENZ.

As of February 12, 2026, LENZ stock price declined to $13.27 with 138,366 million shares trading.

LENZ has a beta of 1.22, meaning it tends to be more sensitive to market movements. LENZ has a correlation of 0.06 to the broad based SPY ETF.

LENZ has a market cap of $401.69 million. This is considered a Small Cap stock.

Last quarter Lenz Therapeutics reported $13 million in Revenue and -$.59 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.09.

The top ETF exchange traded funds that LENZ belongs to (by Net Assets): VTI, IWM, VXF, IBB, XPH.

LENZ has underperformed the market in the last year with a price return of -46.7% while the SPY ETF gained +14.3%. LENZ has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -49.8% and -28.8%, respectively, while the SPY returned +0.5% and -1.6%, respectively.

LENZ support price is $12.74 and resistance is $14.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LENZ shares will trade within this expected range on the day.